Anteris Technologies ( (AU:AVR) ) has provided an announcement.
Anteris Technologies announced the issuance of 5,000 shares of Common Stock via CHESS Depository Interests, raising A$50,000 through the conversion of unlisted options. This move reflects the company’s ongoing efforts to strengthen its financial position and support its operations in the structural heart industry. The announcement signifies compliance with relevant sections of the Corporations Act, indicating transparency and adherence to regulatory standards.
More about Anteris Technologies
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. Founded in Australia and with a significant presence in Minneapolis, USA, the company is science-driven and staffed by a team of multidisciplinary professionals. Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (THV), is designed to treat aortic stenosis and is the first biomimetic valve shaped to mimic a healthy human aortic valve. The valve is made using Anteris’ patented anti-calcification tissue technology, ADAPT®, which has been FDA-cleared and used in over 55,000 patients worldwide.
Average Trading Volume: 3,501
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $175.7M
See more data about AVR stock on TipRanks’ Stock Analysis page.